JERSEY, Channel Islands, April 21, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that its U.S. subsidiary, Quotient Biodiagnostics, Inc. (“Quotient Biodiagnostics”), has signed a national group purchasing agreement with Premier, Inc. (“Premier”), a leading healthcare improvement company. Effective February 1, 2016, this new 36 month agreement enables Premier members to take advantage of specially negotiated pricing and terms for blood bank reagents offered by Quotient Biodiagnostics. Premier unites an alliance of roughly 3,600 U.S. hospitals and 120,000 other providers to transform healthcare.
Quotient Biodiagnostics provides highest quality immunohematology products to blood banks and hospitals and offers a broad line of reagents for blood grouping, including its highly successful ALBAcyte® C3 Coated Red Blood Cells for control of anti-human globulin testing.
“We are pleased and honored to advance our existing relationship with Premier, one of the largest group purchasing organizations in the United States. This new agreement provides an opportunity for us to better serve Premier members and demonstrate our company-wide commitment to quality and value with a superior customer experience,” said Bill Brady, Vice President of Sales at Quotient Biodiagnostics.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.